Immunovia presents data from discovery study at 2024 PancreasFest medical conference
Immunovia (Nasdaq Stockholm: IMMNOV) presented detailed discovery study results for its next-generation early detection test for pancreatic cancer at the PancreasFest 2024 Annual Meeting. The study, the most comprehensive pancreatic cancer proteomics study to date, identified 15 promising protein biomarkers that strongly correlate with pancreatic ductal adenocarcinoma (PDAC). Over 3,000 proteins were evaluated in 329 blood samples from Stage I and II PDAC and non-PDAC matched control patients using Olink multiplex technology and conventional immunoassays. The biomarkers demonstrated the ability to differentiate PDAC cases from non-PDAC controls. This presentation reflects the initial positive data shared in a November 7, 2023 press release.
Immunovia (Nasdaq Stockholm: IMMNOV) ha presentato i risultati dettagliati di uno studio di scoperta per il suo test di rilevamento precoce di nuova generazione per il cancro pancreatico durante il PancreasFest 2024 Annual Meeting. Lo studio, il più completo nel campo della proteomica del cancro pancreatico fino ad oggi, ha identificato 15 promettenti biomarcatori proteici che risultano fortemente correlati con l'adenocarcinoma duttale pancreatico (PDAC). Sono stati valutati oltre 3.000 proteine in 329 campioni di sangue provenienti da pazienti con PDAC di Stadio I e II e pazienti di controllo abbinati non affetti da PDAC, utilizzando la tecnologia multiplex Olink e immunoassay convenzionali. I biomarcatori hanno dimostrato la capacità di differenziare i casi di PDAC dai controlli non affetti. Questa presentazione riflette i dati iniziali positivi condivisi in un comunicato stampa del 7 novembre 2023.
Immunovia (Nasdaq Stockholm: IMMNOV) presentó los resultados detallados de un estudio de descubrimiento para su prueba de detección temprana de nueva generación para el cáncer pancreático en la PancreasFest 2024 Annual Meeting. El estudio, el más completo en la proteómica del cáncer pancreático hasta la fecha, identificó 15 biomarcadores proteicos prometedores que tienen una fuerte correlación con el adenocarcinoma ductal pancreático (PDAC). Se evaluaron más de 3.000 proteínas en 329 muestras de sangre de pacientes con PDAC en etapa I y II y pacientes controles emparejados no PDAC, utilizando la tecnología multiplex de Olink y ensayos inmunológicos convencionales. Los biomarcadores demostraron la capacidad de diferenciar los casos de PDAC de los controles no PDAC. Esta presentación refleja los datos iniciales positivos compartidos en un comunicado de prensa del 7 de noviembre de 2023.
Immunovia (Nasdaq Stockholm: IMMNOV)는 PancreasFest 2024 Annual Meeting에서 췌장암 조기 발견을 위한 차세대 테스트에 대한 자세한 발견 연구 결과를 발표했습니다. 이 연구는 지금까지의 가장 포괄적인 췌장암 단백질체 연구로, 췌장관 선암(PDAC)과 강하게 연관된 15개의 유망한 단백질 바이오마커를 확인했습니다. Olink 다중화 기술과 전통적인 면역측정법을 사용하여 PDAC 1기 및 2기 환자와 비 PDAC 일치 제어 환자 329명의 혈액 샘플에서 3,000개 이상의 단백질을 평가했습니다. 이 바이오마커들은 PDAC 케이스와 비 PDAC 제어를 구분하는 능력을 보여주었습니다. 이 발표는 2023년 11월 7일에 공유된 초기 긍정적인 데이터와 일치합니다.
Immunovia (Nasdaq Stockholm: IMMNOV) a présenté les résultats détaillés d'une étude de découverte pour son test de détection précoce de nouvelle génération pour le cancer du pancréas lors de la PancreasFest 2024 Annual Meeting. L'étude, la plus complète à ce jour sur la protéomique du cancer du pancréas, a identifié 15 biomarqueurs protéiques prometteurs qui sont fortement corrélés avec l'adénocarcinome canalaire pancréatique (PDAC). Plus de 3 000 protéines ont été évaluées dans 329 échantillons de sang de patients atteints de PDAC au stade I et II et de patients témoins appariés non PDAC, en utilisant la technologie multiplex Olink et des immunoessais conventionnels. Les biomarqueurs ont démontré leur capacité à différencier les cas de PDAC des témoins non PDAC. Cette présentation reflète les données initiales positives partagées dans un communiqué de presse du 7 novembre 2023.
Immunovia (Nasdaq Stockholm: IMMNOV) stellte die detaillierten Ergebnisse einer Entdeckungsstudie für seinen next-generation Früherkennungstest für Bauchspeicheldrüsenkrebs auf dem PancreasFest 2024 Annual Meeting vor. Die Studie, die umfassendste Proteomikstudie zu Bauchspeicheldrüsenkrebs bis heute, identifizierte 15 vielversprechende Proteinbiomarker, die stark mit dem ductalen Adenokarzinom der Bauchspeicheldrüse (PDAC) korrelieren. Über 3.000 Proteine wurden in 329 Blutproben von Patienten mit PDAC im Stadium I und II sowie passenden Kontrollen ohne PDAC mithilfe der Olink-Multiplex-Technologie und herkömmlichen Immunoassays bewertet. Die Biomarker zeigten die Fähigkeit, PDAC-Fälle von nicht-PDAC-Kontrollen zu unterscheiden. Diese Präsentation spiegelt die anfänglichen positiven Daten wider, die in einer Pressemitteilung vom 7. November 2023 geteilt wurden.
- Presentation of discovery study results at a prestigious medical conference (PancreasFest 2024)
- Identification of 15 promising protein biomarkers for early detection of pancreatic cancer
- Comprehensive study involving over 3,000 proteins evaluated in 329 blood samples
- Biomarkers showed ability to differentiate PDAC cases from non-PDAC controls
- None.
PancreasFest is an annual conference of physicians and translational researchers with special interest in the pancreas who convene to find new ways to improve the care of patients with pancreatic disease, including pancreatic cancer. It is organized by the Collaborative Alliance for Pancreatic Education and Research. Abstracts submitted to this medical conference undergo a rigorous peer-review and selection process in which only a subset of studies are chosen for presentation at the meeting.
Results presented at PancreasFest reflect a detailed scientific presentation of the initial positive data the company shared in a 7 November 2023 press release.
The discovery study, the most comprehensive pancreatic cancer proteomics study done to date, identified 15 promising protein biomarkers that were shown to strongly correlate with the presence of pancreatic ductal adenocarcinoma (PDAC). These protein biomarkers demonstrated the ability to differentiate PDAC cases from non-PDAC controls. Over 3,000 proteins were evaluated in 329 blood samples from Stage 1 and II PDAC and non-PDAC matched control patients using Olink multiplex technology and conventional immunoassays.
"We are honored to have been chosen to present the discovery study results at this important conference. We look forward to discussing the detailed study data and receiving scientific and clinical insights from this key group of physicians and researchers who are experts in pancreatic cancer," said Norma Palma PhD, Vice President of Clinical and Medical Affairs at Immunovia.
For more information, please contact:
Jeff Borcherding
CEO and President
jeff.borcherding@immunovia.com
Karin Almqvist Liwendahl
Chief Financial Officer
karin.almqvist.liwendahl@immunovia.com
+46 709 11 56 08
Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer.
Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com
CONTACT:
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Press release (PDF) |
View original content:https://www.prnewswire.com/news-releases/immunovia-presents-data-from-discovery-study-at-2024-pancreasfest-medical-conference-302206920.html
SOURCE Immunovia AB
FAQ
What did Immunovia (IMMNOV) present at PancreasFest 2024?
How many proteins and samples were evaluated in Immunovia's (IMMNOV) pancreatic cancer study?
What was the significance of Immunovia's (IMMNOV) presentation at PancreasFest 2024?
When did Immunovia (IMMNOV) initially share the positive data from their pancreatic cancer study?
